Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - The lancet …, 2015 - thelancet.com
Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor
survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …
被引用次数：408 相关文章

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - The Lancet …, 2014 - europepmc.org
Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor
survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - core.ku.dk
BACKGROUND: Patients with muscle-invasive urothelial carcinoma of the bladder have
poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - The Lancet …, 2015 - folia.unifr.ch
METHODS This intergroup, open-label, randomised, phase 3 trial recruited patients from
hospitals across Europe and Canada. Eligible patients had histologically proven urothelial …

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - The Lancet …, 2015 - sonar.ch
METHODS This intergroup, open-label, randomised, phase 3 trial recruited patients from
hospitals across Europe and Canada. Eligible patients had histologically proven urothelial …

[引用][C] Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - 2015 - repository.ubn.ru.nl
BACKGROUND: Patients with muscle-invasive urothelial carcinoma of the bladder have
poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst, P Albers… - The lancet …, 2015 - boris.unibe.ch
BACKGROUND Patients with muscle-invasive urothelial carcinoma of the bladder have poor
survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

GE des Tumeurs Urogénitales… - Lancet …, 2015 - pure.au.dk
BACKGROUND: Patients with muscle-invasive urothelial carcinoma of the bladder have
poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an …

CN Sternberg, I Skoneczna, JM Kerst… - The Lancet …, 2015 - dial.uclouvain.be
BACKGROUND: Patients with muscle-invasive urothelial carcinoma of the bladder have
poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus …

[引用][C] Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): An …

C Sternberg, I Skoneczna, M Kerst, P Albers… - The Lancet …, 2015 - repub.eur.nl
RePub, Erasmus University Repository: Immediate versus deferred chemotherapy after radical
cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC …